سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva pharmaceuticals slovakia s.r.o., slovensko - tiotropiumbromid - 14 - bronchodilatantia, antiasthmatica

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viatris limited, Írsko - tiotropiumbromid - 14 - bronchodilatantia, antiasthmatica

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva, k.s., Česká republika - tiotropiumbromid - 14 - bronchodilatantia, antiasthmatica

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

genesis diagnostics ltd eden research park, henry crabb road littleort, cambridgeshire spojené kráľovstvo veľkej británie a severného Írska -

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cambridge nutritional sciences ltd. eden reasearch par, henry crabb road cb6 1se littleport, cambridgeshire spojené kráľovstvo veľkej británie a severného Írska -

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cambridge nutritional sciences ltd. eden reasearch par, henry crabb road cb6 1se littleport, cambridgeshire spojené kráľovstvo veľkej británie a severného Írska -

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

cambridge nutritional sciences ltd. eden reasearch par, henry crabb road cb6 1se littleport, cambridgeshire spojené kráľovstvo veľkej británie a severného Írska -

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - viacnásobný myelóm - imunosupresíva - imnovid v kombinácii s bortezomib a dexamethasone je indikovaný na liečbu dospelých pacientov s mnohopočetným myelómom, ktorí dostali aspoň jeden pred liečebného režimu vrátane lenalidomide. imnovid v kombinácii s dexametazónom je indikovaný na liečbu dospelých pacientov s relabujúcim a refraktérnym mnohopočetným myelómom, ktorí dostali najmenej dve predchádzajúce liečebných režimov, vrátane lenalidomid a bortezomib, a preukázali progresie ochorenia po poslednej liečby.